1. Home
  2. NSP vs TSHA Comparison

NSP vs TSHA Comparison

Compare NSP & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Insperity Inc.

NSP

Insperity Inc.

SELL

Current Price

$48.75

Market Cap

1.9B

ML Signal

SELL

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$4.37

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NSP
TSHA
Founded
1986
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
NSP
TSHA
Price
$48.75
$4.37
Analyst Decision
Hold
Strong Buy
Analyst Count
5
13
Target Price
★ $51.75
$13.00
AVG Volume (30 Days)
434.2K
★ 3.6M
Earning Date
10-29-2026
11-03-2026
Dividend Yield
★ 4.92%
N/A
EPS Growth
N/A
★ 5.56
EPS
★ 0.97
N/A
Revenue
★ $6,812,000,000.00
$9,773,000.00
Revenue This Year
$1.40
N/A
Revenue Next Year
$4.27
$1,023.00
P/E Ratio
$49.85
★ N/A
Revenue Growth
3.51
★ 17.28
52 Week Low
$18.57
$3.69
52 Week High
$55.90
$7.30

Technical Indicators

Market Signals
Indicator
NSP
TSHA
Relative Strength Index (RSI) 48.75 30.17
Support Level $47.12 $4.37
Resistance Level $55.04 $4.72
Average True Range (ATR) 1.93 0.23
MACD 0.16 -0.01
Stochastic Oscillator 60.42 14.20

Price Performance

Historical Comparison
NSP
TSHA

About NSP Insperity Inc.

Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: